Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ionetix Corporation

Request full access

Pioneering end-to-end radiopharmaceutical provider for pet imaging

Delhi Charter Township, United StatesFounded 2009Biotech & Life Sciences

About Ionetix Corporation

Ionetix Corporation is a radiopharmaceutical technology company that provides isotopes for both diagnostic imaging and therapeutic applications. The company was founded in 2009, commercializing technology originally developed at the MIT Plasma Science and Fusion Center. One of the founders identified is T. Timothy Antaya. The company is currently led by Chairman & CEO Kevin J. Cameron.

The firm's core business revolves around a vertically integrated model that includes the design, engineering, and manufacturing of its proprietary cyclotrons, isotope production, and end-to-end drug manufacturing and distribution. Ionetix's primary clients are healthcare providers and PET programs. The business model for its diagnostic product involves a turnkey solution where Ionetix covers the installation and operational costs of its cyclotrons on or near a hospital's campus, and clients pay on a per-dose basis. This approach aims to make critical cardiac PET imaging more accessible and affordable.

Ionetix has developed the ION-12SC, a compact, superconducting cyclotron for point-of-care production of PET radioisotopes. Its small footprint and lower cost of ownership are significant differentiators from conventional cyclotrons. This system is primarily used to produce Nitrogen-13 (N-13) Ammonia, an FDA-approved radiopharmaceutical for myocardial perfusion PET imaging, which helps in the diagnosis and management of coronary artery disease. The short half-life of N-13 Ammonia necessitates on-site production, which the ION-12SC enables.

Expanding beyond diagnostics, Ionetix has entered the therapeutic space, specifically focusing on Targeted Alpha Therapy (TAT), an emerging cancer treatment. This therapy uses molecules like antibodies or peptides to deliver alpha-emitting radionuclides directly to cancer cells, minimizing damage to surrounding healthy tissue. To support this, Ionetix has established a dedicated manufacturing center in Lansing, Michigan, equipped with a more powerful 30 MeV cyclotron to produce alpha isotopes. The company is focusing on producing Actinium-225 (Ac-225) and Astatine-211 (At-211), two isotopes with significant potential in TAT but which have faced supply chain challenges. In August 2024, the company announced a financing round with investors including Eli Lilly and Company and Tees River to expand its cyclotron network and scale the supply of these alpha-emitters.

Source: Dealroom company data

At a glance

Status
Operational
Employees
60
Open positions
6
Dealroom signal
34.0/100
Industry
Health, Energy
Sub-industry
Pharmaceutical, BioTechnology
Sector
Veterinary, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology
Big Data, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Apr 2026 $30M $120M Undisclosed ↗
CONVERTIBLEOther financing Aug 2024 $10M — Eli Lilly ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Ionetix Corporation website traffic

Latest recorded traffic for Ionetix Corporation is 3K monthly website visits, up 42.9% over the last three months. Ionetix Corporation's team declined 3.2% over the past year.

Latest monthly visits3K 3-month web change+42.9% 1-year team growth-3.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ionetix Corporation in the Delhi Charter Township ecosystem

Live from Dealroom

The Ionetix Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Eli Lilly

Series B and later1 investor entered at this stage

  • POINT Biopharma
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ionetix Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ionetix Corporation’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.